Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 16, 2020 - Issue 9
Submit an article Journal homepage
1,528
Views
0
CrossRef citations to date
0
Altmetric
Review

Vaccines from the Spanish Influenza as a firm foundation for new developments

John S. OxfordBlizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UKCorrespondence[email protected]
&
Douglas GillBlizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Pages 2051-2055 | Received 01 Apr 2020, Accepted 30 Jun 2020, Published online: 12 Aug 2020

References

  • Piot P, Larson HJ, O’Brien KL, N’kengasong J, Ng E, Sow S, Kampmann B. Immunisation: vital progress, unfinished agenda. Nature. 2019;575:119. doi:10.1038/s41586-019-1656-7.
  • Thompson ES. Influenza or epidemic catarrhal fever. London (UK): Percival & Co.; 1890. p. 490.
  • Wright AE. Observations on the pharmaco-therapy of pneumococcus infections. Lancet. 1912;180:1633–37. Lancet. 1912;180;1701–5. doi:10.1016/S0140-6736(01)41480-2.
  • Oxford JS, Gill D. Unanswered questions about the 1918 influenza pandemic: origin, pathology, and the virus itself. Lancet Infect Dis. 2018 June 20;18:e348–e354. doi:10.1016/S1473-3099(18)30359-1.
  • Taubenberger JK, Palese P. The origin and virulence of the 1918 “Spanish” influenza virus. In: Kawaoka Y, editor. Influenza virology, current topics. Norfolk (UK): Caister Academic Press; 2006. p. 299–321.
  • Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza. J Infect Dis. 2008;198-vii:962–70. doi:10.1086/591708.
  • Wright AE. Prophylactic inoculation against pneumococcus infections. Lancet. 1914;183:1–10. Lancet. 1914;183:87–95. doi:10.1016/S0140-6736(01)56370-9.
  • Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226.
  • Penfold WJ. Report on the influenza pandemic in Victoria, Australia. Government Printer; 1919.
  • Smith W, Andrewes CH, Laidlaw PP, Smith W. A virus obtained from influenza patients. Lancet. 1933;ii:66. doi:10.1016/S0140-6736(00)78541-2.
  • Alexandrova GI, Smorodintsev AA. The reactive and immunogenic properties and epidemiological effectiveness of further attenuated influenza virus vaccinal strains. Vopr Virusol. 1965;10:67–73.
  • Massab HF. Adaptation and growth characteristics of cold adapted influenza virus at twenty-five degrees centigrade. Nature. 1967;213:612. doi:10.1038/213612a0.
  • Reichert TA, Sugaya N, Fedson D, Glezen WP, Simonsen L, Tashiro M. Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2012;344:889–96. doi:10.1056/NEJM200103223441204.
  • Oxford JS, Kellam P, Collier L. Human virology. London: Oxford University Press; 2016. p. 350.
  • Werner GH. Immunité croisée hétérotypique chez la souris entre virus grippoux humains de types A et A2. Comptes Rendus de l’Academie des Sciences. 1967;263:1913–16.
  • Schulman JL, Kilbourne ED. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol. 1965;89:170–74. doi:10.1128/JB.89.1.170-174.1965.
  • Laver WG. Structural studies on the protein sub units from three strains of influenza virus. J Mol Biol. 1964;9:109. doi:10.1016/S0022-2836(64)80094-2.
  • Oxford JS, Schild GC. Immunological and chemical studies of influenza matrix (M) polypeptides. Virology. 1976;74:394–402. doi:10.1016/0042-6822(76)90345-7.
  • Schild GC, Oxford JS, Virelizier JL. The immune response to influenza. In: Beers RF, Bassett EG, editors. The role of immunological factors in infectious allergic and auto-immune processes. New York (USA): Raven Press; 1976. p. 116–48.
  • Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge with baculovirus expressed M2 protein. Vaccine. 1995;13:1399–402. doi:10.1016/0264-410X(95)92777-Y.
  • Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A ‘universal’ human influenza A vaccine. Virus Res. 2004;103:173–76. doi:10.1016/j.virusres.2004.02.030.
  • Pleguezueios O, Robinson S, Fernandez A, Stoloff GA, Mann A, Gilbert A, Balaratnam G, Wilkinson T, Lambkin-Williams R, Oxford J, et al. A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans. Clin Vaccine Immunol. 2015;22:828. doi:10.1128/CVI.00098-15.
  • Lillie P, Berthoud TK, Powell TJ. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012;55:19–25. doi:10.1093/cid/cis327.
  • Eyre JWH, Lowe EC. Report upon the autumn influenza epidemic (1918) as it affected the N.Z.E.F. in the United Kingdom. Lancet. 1919 April 5;193:553–56. doi:10.1016/S0140-6736(01)25676-1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.